Aslan Pharmaceuticals Ltd ADR
(ASLN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2022 | 09-2022 | 06-2022 | 03-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -51,283 | N/A | -25,972 | N/A | -31,591 |
| Depreciation Amortization | 332 | N/A | 143 | N/A | 282 |
| Accounts payable and accrued liabilities | 9,668 | N/A | 6,326 | N/A | 797 |
| Other Working Capital | 9,352 | N/A | 7,118 | N/A | -4,121 |
| Other Operating Activity | -6,473 | 0 | -4,527 | 0 | 636 |
| Operating Cash Flow | $-38,405 | $N/A | $-16,912 | $N/A | $-33,996 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 88 | N/A | -16,513 | N/A | N/A |
| PPE Investments | -26 | N/A | -18 | N/A | -36 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | 21 |
| Purchase Sale Intangibles | N/A | N/A | N/A | N/A | -12 |
| Other Investing Activity | 353 | 0 | 0 | 0 | -13 |
| Investing Cash Flow | $415 | $N/A | $-16,530 | $N/A | $-28 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 5,000 | N/A | 5,000 | N/A | 20,000 |
| Debt Repayment | N/A | N/A | N/A | N/A | -7,784 |
| Common Stock Issued | N/A | N/A | N/A | N/A | 102,603 |
| Other Financing Activity | -275 | 0 | -149 | 0 | -4,952 |
| Financing Cash Flow | $4,725 | $N/A | $4,851 | $N/A | $109,867 |
| Beginning Cash Position | 90,168 | N/A | 90,168 | N/A | 14,324 |
| End Cash Position | 56,902 | N/A | 61,577 | N/A | 90,168 |
| Net Cash Flow | $-33,266 | $N/A | $-28,592 | $N/A | $75,844 |
| Free Cash Flow | |||||
| Operating Cash Flow | -38,405 | N/A | -16,912 | N/A | -33,996 |
| Capital Expenditure | -27 | N/A | -18 | N/A | -36 |
| Free Cash Flow | -38,432 | 0 | -16,930 | 0 | -34,032 |